tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

ResMed price target raised to $305 from $283 at Baird

Baird analyst David Rescott raised the firm’s price target on ResMed (RMD) to $305 from $283 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results but sees valuation as stretched but fundamentals remain solid.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1